DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...
CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Dose-dense, every-2-week adjuvant chemotherapy using doxorubicin/cyclophosphamide (AC; 60/600 mg/m 2 every 2 weeks × four cycles) followed by paclitaxel (175 mg/m 2 ...
Akebia Therapeutics, Inc. announced the publication of pre-specified analyses from its global phase 3 clinical trials of vadadustat for treating anemia in chronic kidney disease (CKD) in the Journal ...
In a study of incident dialysis patients, the HIF-PHI agent daprodustat demonstrated safety and efficacy similar to that of the ESA darbepoetin alfa. Daprodustat is a potential oral alternative to ...
DENVER—Patients with end-stage renal disease who receive predialysis intravenous iron therapy are more likely to start hemodialysis with higher hemoglobin (Hb) levels and to achieve better Hb control ...
Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in ...
Daily treatment with oral daprodustat was noninferior to standard erythropoiesis-stimulating agents (ESAs) for both increasing hemoglobin levels and for cardiovascular safety in patients with chronic ...
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women Two 16-week randomized, double-blind, placebo-controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback